Abstract:Background Antipsychotic drugs improve schizophrenia symptoms and reduce the frequency of relapse, but treatment response is highly variable. Little is known about the genetic factors associated with treatment response. We did a genome-wide association study of antipsychotic treatment response in patients with schizophrenia. Methods The discovery cohort comprised patients with schizophrenia from 32 psychiatric hospitals in China that are part of the Chinese Antipsychotics Pharmacogenomics Consortium. Patients who met inclusion criteria were randomly assigned (1:1:1:1:1:1) to six groups (olanzapine, risperidone, quetiapine, aripiprazole, ziprasidone, and haloperidol or perphenazine; those assigned to haloperidol or perphenazine were subsequently assigned [1:1] to one or the other) for 6 weeks. Antipsychotic response was quantified with percentage change on the Positive and Negative Syndrome Scale. Single-nucleotide polymorphisms (SNPs) were tested for their association with treatment response. Linkage-disequilibrium-independent SNPs that exhibited potential associations (ie, p < 1 x 10(-5)) were tested in a validation cohort comprising patients from the Chinese Antipsychotics Pharmacogenetics Consortium from five collaborative hospitals, who were treated with olanzapine, risperidone, or aripiprazole for 8 weeks. Findings The discovery cohort contained 2413 patients and the validation cohort 1379 patients. In the discovery cohort, we identified three novel SNPs (rs72790443 in MEGF10 [p=1.37 x 10(-8)], rs1471786 in SLC1A1 [p=1.77 x 10(-8)], and rs9291547 in PCDH7 [p=4.48x 10(-8)]) that were associated with antipsychotic treatment response at a genome-wide significance level. These associations were confirmed in the validation cohort (p < 0.05). In the combined sample of the discovery and validation cohorts, we identified five novel loci showing genome-wide significant associations with general antipsychotic treatment response (rs72790443 in MEGF10 [p=1.40 x 10(-9)], rs1471786 in SLC1A1 [p=2.33 x 10(-9)], rs9291547 in PCDH7 [p=3.24 x rs9291547 in PCDH7 [p=3.24 x 10(-9)], rs12711680 in CNTNAP5 [p=2.12 x 10(-9)], and rs6444970 in TNIK [p=4.85 x 10(-8)]).], rs12711680 in CNTNAP5 [p=2.12 x 10(-8)], and rs6444970 in TNIK [p=4.85 x 10(-8)]). In antipsychotic-specific groups, after the combination of results from both samples, the rs2239063 SNP in CACNA1C was associated with treatment response to olanzapine (p=1.10 x 10(-8)), rs16921385 in SLC1A1 was associated with treatment response to risperidone (p=4.40 x 10(-8)), and rs17022006 in CNTN4 was associated with treatment response to aripiprazole (p=2.58 x 10(-8)). Interpretation We have identified genes related to synaptic function, neurotransmitter receptors, and schizophrenia risk that are associated with response to antipsychotics. These findings improve understanding of the mechanisms underlying treatment responses, and the identified biomarkers could eventually guide choice of antipsychotic in patients with schizophrenia.

Functional Magnetic Resonance Imaging in a Single Schizophrenia Patient with Voluntary Control over Auditory Verbal Hallucinations

Ethnicity-dependent Effects of Zinc Finger 804A Variant on Schizophrenia: a Systematic Review and Meta-Analysis

Meta-Analysis of Genome Wide Association Studies Showed Polymorphisms on 2P16.1, 6P22.1 and 10Q24.32 Associated with Schizophrenia in Chinese Han Population

Association Betweenscapandsrebf1gene Polymorphisms and Metabolic Syndrome in Schizophrenia Patients Treated with Atypical Antipsychotics

Genome-wide association study implicates lipid pathway dysfunction in antipsychotic-induced weight gain: multi-ancestry validation

A genome-wide association study for quantitative traits in schizophrenia in China.

Testing the role of genetic variation of the MC4R gene in Chinese population in antipsychotic-induced metabolic disturbance

Genome-Wide Association Study Suggested Theptprdpolymorphisms Were Associated with Weight Gain Effects of Atypical Antipsychotic Medications

TOX and ADIPOQ Gene Polymorphisms Are Associated with Antipsychotic-Induced Weight Gain in Han Chinese

Pharmacogenetic Study of Antipsychotic-Induced Lipid and BMI Changes in Chinese Schizophrenia Patients: A Genome-Wide Association Study

Positive association between ALDH1A2 and schizophrenia in the Chinese population.

Association Study of Polymorphisms in Neuronal Nicotinic Acetylcholine Receptor Subunit Genes with Schizophrenia in the Han Chinese Population

Association Studies of Genomic Variants with Treatment Response to Risperidone, Clozapine, Quetiapine and Chlorpromazine in the Chinese Han Population

[Association of -2548G/A Functional Polymorphism in the Promoter Region of Leptin Gene with Antipsychotic Agent-Induced Weight Gain].

Association between Ghrelin gene (GHRL) polymorphisms and clinical response to atypical antipsychotic drugs in Han Chinese schizophrenia patients

Association of A2BP1 Gene Polymorphism with Olanzapine Induced Bodyweight Gain

Five Novel Loci Associated with Antipsychotic Treatment Response in Patients with Schizophrenia: a Genome-Wide Association Study

Association study of a genetic variant in the long intergenic noncoding RNA (linc01080) with schizophrenia in Han Chinese

A Comprehensive Meta-Analysis of Znf804a Snps in the Risk of Schizophrenia among Asian Populations

Association analysis between the rs11136000 single nucleotide polymorphism in clusterin gene, rs3851179 single nucleotide polymorphism in clathrin assembly lymphoid myeloid protein gene and the patients with schizophrenia in the Chinese population

Identification of a functional SNP rs7304782 at schizophrenia risk locus 12q24.31 and validation of its association with schiz ophrenia in Chinese populations